44 related articles for article (PubMed ID: 12115198)
21. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
22. The cost-effectiveness of vaccination against Lyme disease.
Shadick NA; Liang MH; Phillips CB; Fossel K; Kuntz KM
Arch Intern Med; 2001 Feb; 161(4):554-61. PubMed ID: 11252114
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
[TBL] [Abstract][Full Text] [Related]
24. Vaccination for Lyme disease: cost-effectiveness versus cost and value.
Sigal LH
Arthritis Rheum; 2002 Jun; 46(6):1439-42. PubMed ID: 12115172
[No Abstract] [Full Text] [Related]
25. American Academy of Pediatrics. Committee on Infecious Diseases. Prevention of Lyme disease.
Pediatrics; 2000 Jan; 105(1 Pt 1):142-7. PubMed ID: 10617720
[TBL] [Abstract][Full Text] [Related]
26. The Lyme disease vaccine--a public health perspective.
Shen AK; Mead PS; Beard CB
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s247-52. PubMed ID: 21217171
[TBL] [Abstract][Full Text] [Related]
27. Vaccines against Lyme disease: What happened and what lessons can we learn?
Poland GA
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s253-8. PubMed ID: 21217172
[TBL] [Abstract][Full Text] [Related]
28. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
29. Strategies for primary and secondary prevention of Lyme disease.
Corapi KM; White MI; Phillips CB; Daltroy LH; Shadick NA; Liang MH
Nat Clin Pract Rheumatol; 2007 Jan; 3(1):20-5. PubMed ID: 17203005
[TBL] [Abstract][Full Text] [Related]
30. Human Lyme disease vaccines: past and future concerns.
Nardelli DT; Munson EL; Callister SM; Schell RF
Future Microbiol; 2009 May; 4(4):457-69. PubMed ID: 19416014
[TBL] [Abstract][Full Text] [Related]
31. Lyme vaccine: issues and controversies.
Rahn DW
Infect Dis Clin North Am; 2001 Mar; 15(1):171-87. PubMed ID: 11301814
[TBL] [Abstract][Full Text] [Related]
32. The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review.
Mac S; da Silva SR; Sander B
PLoS One; 2019; 14(1):e0210280. PubMed ID: 30608986
[TBL] [Abstract][Full Text] [Related]
33. The prevention of Lyme disease with vaccine.
Poland GA; Jacobson RM
Vaccine; 2001 Mar; 19(17-19):2303-8. PubMed ID: 11257352
[TBL] [Abstract][Full Text] [Related]
34. Pediatric immunization for the future. Lyme disease vaccine and beyond.
Lutwick LI; Abramson JM
Pediatr Clin North Am; 2000 Apr; 47(2):465-79, viii. PubMed ID: 10761515
[TBL] [Abstract][Full Text] [Related]
35. The rise and fall of the lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public health.
Aronowitz RA
Milbank Q; 2012 Jun; 90(2):250-77. PubMed ID: 22709388
[TBL] [Abstract][Full Text] [Related]
36. The latest evidence on Lyme disease.
Pearson S
J Fam Health; 2016; 26(3):26-9. PubMed ID: 27498520
[No Abstract] [Full Text] [Related]
37. [Prevention and management of Lyme disease: On complexity and the need to take into consideration various psycho-social factors].
Puppo C; Préau M
Sante Publique; 2019 May; S1(HS):65-71. PubMed ID: 31210492
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of the Lyme disease vaccine.
Hsia EC; Chung JB; Schwartz JS; Albert DA
Arthritis Rheum; 2002 Jun; 46(6):1651-60. PubMed ID: 12115198
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
